Table 1. Patient and tumor characteristics stratified by nuclear RB1CC1 expression.
Feature | Number | Nuclear RB1CC1 | p-Value | |||
negative | (%) | positive | (%) | |||
Menopause | 0.1204 | |||||
Pre- | 142 | 37 | (37) | 105 | (47) | |
Post- | 182 | 62 | (62) | 120 | (53) | |
anti-Estrogen therapy | 0.0540 | |||||
none | 85 | 33 | (33) | 52 | (23) | |
performed | 239 | 66 | (67) | 173 | (77) | |
Chemotherapy | <0.0001 | |||||
none | 179 | 33 | (33) | 146 | (65) | |
performed | 145 | 66 | (67) | 79 | (35) | |
Radiation | 0.1248 | |||||
none | 108 | 27 | (27) | 81 | (36) | |
performed | 216 | 72 | (73) | 144 | (64) | |
T grade: tumor size | 0.0805 | |||||
≤T1 | 138 | 35 | (35) | 103 | (46) | |
T2≤ | 186 | 64 | (65) | 122 | (54) | |
Nodes | 0.0567 | |||||
negative | 210 | 56 | (58) | 154 | (69) | |
positive | 111 | 41 | (43) | 70 | (31) | |
Stage: TNM class | 0.2605 | |||||
≤IIA | 228 | 64 | (67) | 164 | (73) | |
IIB≤ | 93 | 32 | (33) | 61 | (27) | |
ER | 0.0689 | |||||
positive | 188 | 50 | (51) | 138 | (61) | |
negative | 136 | 49 | (49) | 87 | (39) | |
PR | 0.0003 | |||||
positive | 170 | 37 | (37) | 133 | (59) | |
negative | 154 | 62 | (63) | 92 | (41) | |
HER2 | 0.1553 | |||||
negative | 290 | 85 | (86) | 205 | (91) | |
positive | 34 | 14 | (14) | 20 | (9) | |
Triple Negative | 0.0003 | |||||
others | 237 | 59 | (60) | 178 | (79) | |
triple negative | 87 | 40 | (40) | 47 | (21) | |
p53 | 0.3200 | |||||
normal | 244 | 71 | (72) | 173 | (77) | |
abnormal | 80 | 28 | (28) | 52 | (23) | |
RB1 | 0.0833 | |||||
positive | 308 | 91 | (92) | 217 | (96) | |
negative | 16 | 8 | (8) | 8 | (4) | |
RB1CC1 | ------ | |||||
positive | 225 | 0 | (0) | 225 | (100) | |
negative | 99 | 99 | (100) | 0 | (0) | |
RB1CC1/RB1/p53 | ------ | |||||
normal | 169 | 0 | (0) | 169 | (75) | |
abnormal | 155 | 99 | (100) | 56 | (25) |
Chi-square and Fisher's exact tests was used to evaluate the relationships between clinical parameters and nuclear RB1CC1 expression. p-value <0.05, statistically significant.